



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/932,128	08/16/2001	Juan Yguerabide	A9372	5342
57904 7590 03/17/2009 INVITROGEN C/O INTELLEVATE Sughrue Mion PLLC P.O. BOX 52050 MINNEAPOLIS, MN 55402				
EXAMINER				
YANG, NELSON C				
ART UNIT		PAPER NUMBER		
1641				
MAIL DATE		DELIVERY MODE		
03/17/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/932,128

Applicant(s)

YGUERABIDE ET AL.

Examiner

Nelson Yang

Art Unit

1641

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 December 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 49-52, 55, 71-73, 76, 80, 84, 166-172, 176-181, 217 and 218 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 49-52, 55, 71-73, 76, 80, 84, 166-172, 176-181, 217 and 218 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 16 August 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Final Drawing (PTO-940)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Response to Amendment

1. Claims 49-52, 55, 71-73, 76, 80, 84, 166-172, 176-181, 217, 218 are currently pending.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. Claims 49-52, 55, 76, 166-172, 176-179, 217, 218 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nicoli et al. [US 4,647,544] in view of Roth [Roth, The preparation of protein A-gold complexes with 3nm and 15 nm gold apticles and their use in labeling multiple antigens on ultra-thin sections, 1982 Histochemical Journal 14: pp.791-801].

With respect to claims 49, 166, Nicoli et al. teach colloidal gold particles which have been coated with a variety of macromolecules such as avidin, lectins, IgG in the size range of 20 to 500 nm (column 15, lines 25-35), which would therefore have the inherent feature of maximum wavelength absorption from 525 nm to about 635 nm, as evidenced by applicant's own specification (see para. 254, table 2). Although Nicoli et al. do not specify that the gold particles are further coated with a surface coat of gold, the surface of the colloidal gold particles taught by Nicoli et al. would also be gold, and therefore the particles would structurally be the same. These particles are found in homogenous immunoassays where analytes are detected using

optical interference and specifically a Bragg scattering peak (column 5, lines 58-65). Nicolo et al. fail to teach that the coefficient of variation in size of the population of particles is less than 5%.

Roth, however, teaches the use of a population of monodisperse 15 nm gold particles (p. 792, para. 3). Since the 15 nm gold particles are monodisperse, they would have a variation of less 5 %, as monodisperse particles have the same size, shape and mass. Roth teach that this allows for the visualization of two different antigens when used in conjunction with a second population of monodisperse particles of a different size (p. 794. para. 2). For this reason, it would further have been obvious to one of ordinary skill in the art for the particles within each population in the invention of Roth to vary less than 5% in size or diameter, and this would potentially affect the clearly distinguish between the labeling of different antigens.

Furthermore although neither Nicoli et al. or Roth et al. do not specify that the particles have a maximum absorption wavelengths of from about 525 nm to about 635 nm, this would be an inherent feature of the gold particles taught by Nicoli et al. and Roth, as the particles have diameters that fall within the ranges disclosed by applicant that would result in a maximum absorption wavelengths of from about 525 nm to about 635 nm.

Therefore, it would have been obvious for the microspheres of Nicoli et al. to have precise size ranges varying no more than 5%, as this would allow for the visualization of two different antigens when used in conjunction with a second population of monodisperse particles of a different size. It would further have been obvious for the particles have a maximum absorption wavelengths of from about 525 nm to about 635 nm through normal optimization procedures known in the art.

4. With respect to claims 50-52, Nicoli et al. teach colloidal gold particles coated with avidin and IgG (column 15, lines 25-35). Although Nicoli et al. do not specifically recite that proteins do not significantly interact with light in the visible region of the spectrum, this property is inherent in proteins, and therefore would be anticipated by Nicoli et al. and Rembaum et al.
5. With respect to claim 55, the particles taught by Nicoli et al. are spherical (fig. 4C).
6. With respect to claim 76, Nicoli et al. teach colloidal gold particles which have been coated with a variety of macromolecules such as avidin, lectins, IgG in the size range of 20 to 500 nm (column 15, lines 25-35)
7. With respect to claim 167, Nicoli et al. teach different specific antibodies for binding to different antigens (column 23, lines 42-55).
8. With respect to claims 168-172, 176-179, 217, 218, Nicoli et al. teach colloidal gold particles which have been coated with a variety of macromolecules such as avidin, lectins, IgG in the size range of 20 to 500 nm (column 15, lines 25-35),
9. Claims 71-72 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nicoli et al. [US 4,647,544] in view of Roth [Roth, The preparation of protein A-gold complexes with 3nm and 15 nm gold particles and their use in labeling multiple antigens on ultra-thin sections, 1982 Histochemical Journal 14: pp.791-801], as applied to claim 49 above, and further in view of Rembaum et al. [US 4,929,400].
10. With respect to claims 71-72, Nicoli et al. and Roth teach the invention as discussed above, but fail to explicitly teach that the gold particles comprise a magnetic or ferroelectric material.

Rembaum et al., however, teach microspheres created from polymers, proteins, waxes, starches, glasses, magnetic, and metals to impart various different properties to the particles (column 3, lines 40-50, column 4, lines 35-50), and having precise size range with diameters below 1000 Angstroms (column 8, lines 41-54, lines 55-69). Rembaum et al. further teach that the microspheres may comprise magnetic material (column 4, lines 1-10), in order to allow for magnetic separation of analytes from a mixture (column 7, lines 35-60).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention for the particles of Nicoli et al. to comprise magnetic material, so that analytes may be separated from a mixture magnetically, and to impart various different optical properties to the particles.

11. Claims 73, 80, 84, are rejected under 35 U.S.C. 103(a) as being unpatentable over Nicoli et al. [US 4,647,544] in view of Roth [Roth, The preparation of protein A-gold complexes with 3nm and 15 nm gold apticles and their use in labeling multiple antigens on ultra-thin sections, 1982 Histochemical Journal 14: pp.791-801] and in view of Rembaum et al. [US 4,929,400], as applied to claim 49 above, and further in view of Siiman et al. [US 5,552,086].

With respect to claims 73, 80, 84, Nicoli et al. and Roth teach the invention as discussed above, but fail to explicitly teach that the gold particles comprise a magnetic or ferroelectric material or silver.

Rembaum et al., however, teach microspheres created from polymers, proteins, waxes, starches, glasses, magnetic, and metals to impart various different properties to the particles (column 3, lines 40-50, column 4, lines 35-50), and having precise size range with diameters

below 1000 Angstroms (column 8, lines 41-54, lines 55-69). Rembaum et al. further teach that the microspheres may comprise magnetic material (column 4, lines 1-10), in order to allow for magnetic separation of analytes from a mixture (column 7, lines 35-60).

Siiman et al. further disclose that using microstructural gold or silver bumps on microspheres, gold and silver coated particles can be distinguished from each other (column 3, lines 28-50), as they would be with finely dispersed pure gold or silver particles of the same size (column 4, lines 5-15).

Therefore, it would have been obvious to one of ordinary skill in the art at the time of the invention for the particles of Nicoli et al. to comprise magnetic material and silver, as suggested by Rembaum et al. and Siiman et al., so that analytes may be separated from a mixture magnetically, and to impart various different optical properties to the particles such that different populations of particles would be distinguishable from one another, thus allowing for labeling of different analytes and antigens.

12. Claims 180, 181 is rejected under 35 U.S.C. 103(a) as being unpatentable over Nicoli et al. [US 4,647,544] in view of Roth [Roth, The preparation of protein A-gold complexes with 3nm and 15 nm gold apticles and their use in labeling multiple antigens on ultra-thin sections, 1982 Histochemical Journal 14: pp.791-801], as applied to claim 49 above, and further in view of Tarcha et al. [US 5,567,628].

With respect to claims 180, 181, Nicoli et al. discloses populations of gold particles and further comprising antibodies, but fails to teach that the antibodies are anti-biotin, anti-fluorescein or anti-digoxin antibodies.

Tarcha et al., however teach the use of anti-biotin antibodies as a means for attaching biotinylated antibodies (column 23, lines 20-45), thus rendering the particles much more versatile.

Therefore it would have been obvious in the invention of Nicoli et al. and Rembaum et al. to have particles comprising anti-biotin antibodies, as suggested by Tarcha et al., due to the greater versatility it provides the particles, allowing a greater variety of different antibodies to be attached.

Response to Arguments

13. Applicant's arguments with respect to claims 49-52, 55, 71-73, 76, 80, 84, 166-172, 176-161, 217, 218 have been considered but are moot in view of the new ground(s) of rejection.

14. The Office notes that Rembaum does in fact teach that monodisperse particles which can be made from metal (column 3, lines 40-45), which would suggest variation of less than 5%, since the term monodisperse would suggest that the particles are the same size, shape and mass, as opposed to polydisperse particles. The Office, however, acknowledges that the Rembaum reference does not clearly establish that the monodisperse particles would fall within a range of 10 nm to about 140 nm when a metal is used, as it is not clear whether the metal or metal compound particles referred to on column 8, lines 40-45), as cited in the prior action, refer to the monodisperse particles themselves, or to particles that are used to compose the monodisperse particles. Therefore, the Roth reference has been brought in to establish that monodisperse metal particles with a diameter between 10 nm and 140 nm can be formed.

Conclusion

15. No claims are allowed.
16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nelson Yang whose telephone number is (571)272-0826. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (571)272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

17. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Nelson Yang/
Patent Examiner, Art Unit 1641